- Home
- CRMD vs VALN Comparison
CRMD vs VALN Comparison
Compare CRMD & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRMD | VALN |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.8M | 875.7M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRMD | VALN |
|---|---|---|
| Price | $6.45 | $10.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $14.67 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 1.4M | 17.9K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 780.00 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $311,709,000.00 | N/A |
| Revenue This Year | $1.10 | $2.58 |
| Revenue Next Year | N/A | $4.43 |
| P/E Ratio | $3.14 | ★ N/A |
| Revenue Growth | ★ 617.03 | N/A |
| 52 Week Low | $5.60 | $5.43 |
| 52 Week High | $17.43 | $12.25 |
Technical Indicators
Market Signals| Indicator | CRMD | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 48.35 |
| Support Level | $6.13 | $9.85 |
| Resistance Level | $7.44 | $10.46 |
| Average True Range (ATR) | 0.30 | 0.41 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 22.81 | 18.35 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.